Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Krystal Biotech's Enterprise Value is €8,942.3 Mil.
Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €153.6 Mil. Therefore, Krystal Biotech's EV-to-EBIT ratio for today is 58.23.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Krystal Biotech's Enterprise Value is €8,942.3 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €159.3 Mil. Therefore, Krystal Biotech's EV-to-EBITDA ratio for today is 56.14.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Krystal Biotech's Enterprise Value is €8,942.3 Mil.
Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €358.7 Mil. Therefore, Krystal Biotech's EV-to-Revenue ratio for today is 24.93.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Krystal Biotech's Enterprise Value is €8,942.3 Mil.
Krystal Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €204.1 Mil. Therefore, Krystal Biotech's EV-to-FCF ratio for today is 43.81.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Krystal Biotech (FRA:4KB) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Krystal Biotech's current Enterprise Value is €8,942.3 Mil.
Krystal Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €153.6 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Krystal Biotech's current Enterprise Value is €8,942.3 Mil.
Krystal Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €159.3 Mil.
Krystal Biotech's current Enterprise Value is €8,942.3 Mil.
Krystal Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €358.7 Mil.
Krystal Biotech's current Enterprise Value is €8,942.3 Mil.
Krystal Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €215.2 Mil.
Krystal Biotech's current Enterprise Value is €8,942.3 Mil.
Krystal Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €204.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech Enterprise Value Related Terms
Krystal Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, PRAX, TECH: Enterprise Value Comparison
For the Biotechnology subindustry, Krystal Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Krystal Biotech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €8,942.3 Mil mean?
Krystal Biotech (FRA:4KB) has a Enterprise Value of €8,942.3 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Enterprise Value too high?
Krystal Biotech's current Enterprise Value is €8,942.3 Mil. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Enterprise Value compare to NUVL and PRAX?
Krystal Biotech's Enterprise Value of €8,942.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Enterprise Value is €8,942.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €313.40 — trading 19.3% above its estimated fair value. The current Enterprise Value is €8,942.3 Mil. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Enterprise Value is €8,942.3 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
Enterprise Value: €8,942.3 Mil
GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
